Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Intravesical Instillation of EOQUIN™ in High Risk Superficial Bladder Cancer

NCT00141531 is registered in ClinicalTrials.gov with Spectrum Pharmaceuticals, Inc as lead sponsor.

NCT NCT00141531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00141531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Intravesical Instillation of EOQUIN™ in High Risk Superficial Bladder Cancer
Lead sponsor
Spectrum Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
December 31, 2009
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder neoplasms